Cited 3 time in
COX-2 Acts as a Key Mediator of Trifluoperazine-induced Cell Death in U87MG Glioma Cells
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, J. | - |
| dc.contributor.author | Jeong, J.Y. | - |
| dc.contributor.author | Kang, S.S. | - |
| dc.date.accessioned | 2023-01-04T05:01:01Z | - |
| dc.date.available | 2023-01-04T05:01:01Z | - |
| dc.date.issued | 2022-12 | - |
| dc.identifier.issn | 0250-7005 | - |
| dc.identifier.issn | 1791-7530 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/29918 | - |
| dc.description.abstract | Background/Aim: Glioblastoma multiforme (GBM) is one of the most common brain tumors with a poor prognosis. Previously, we reported that trifluoperazine (TFP), a well-known antipsychotic, has anti-glioma activity through the modulation of intracellular calcium levels. The present study aimed to investigate the anti-cancer mechanism of action of TFP on glioma cells. Materials and Methods: The effect of TFP on U87MG cells was examined using a viability assay, flow cytometry, enzyme-linked immunosorbent assay, quantitative real-time PCR, western blot analysis, colony formation, and immunocytochemistry. Results: TFP treatment decreased cell viability. To test the possible involvement of COX-2 in the anticancer activity of TFP on U87MG cells, a COX-2 inhibitor was applied. COX-2 inhibitor pretreatment restored TFP-induced reduction in viability to the control level. Additionally, TFP-induced changes in the apoptotic cell population, production of prostaglandins (PGE2, PGD2, 15d-PGJ2), and nuclear translocation of peroxisome proliferator-activated receptor γ (PPARγ) were ameliorated by COX-2 inhibitor pretreatment. Conclusion: TFP suppressed the proliferation of U87MG glioma cell in a COX-2/PPARγ-dependent manner. © 2022 International Institute of Anticancer Research. All rights reserved. | - |
| dc.format.extent | 9 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | International Institute of Anticancer Research | - |
| dc.title | COX-2 Acts as a Key Mediator of Trifluoperazine-induced Cell Death in U87MG Glioma Cells | - |
| dc.type | Article | - |
| dc.publisher.location | 그리이스 | - |
| dc.identifier.doi | 10.21873/anticanres.16084 | - |
| dc.identifier.scopusid | 2-s2.0-85143185271 | - |
| dc.identifier.wosid | 000916216200009 | - |
| dc.identifier.bibliographicCitation | Anticancer Research, v.42, no.12, pp 5773 - 5781 | - |
| dc.citation.title | Anticancer Research | - |
| dc.citation.volume | 42 | - |
| dc.citation.number | 12 | - |
| dc.citation.startPage | 5773 | - |
| dc.citation.endPage | 5781 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordPlus | UP-REGULATION | - |
| dc.subject.keywordPlus | MOLECULAR-MECHANISM | - |
| dc.subject.keywordPlus | APOPTOSIS | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordPlus | THERAPY | - |
| dc.subject.keywordPlus | CYCLOOXYGENASE-2 | - |
| dc.subject.keywordPlus | PROLIFERATION | - |
| dc.subject.keywordPlus | CALMODULIN | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordAuthor | COX-2 | - |
| dc.subject.keywordAuthor | Glioblastoma multiforme | - |
| dc.subject.keywordAuthor | PPARγ | - |
| dc.subject.keywordAuthor | Trifluoperazine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
